{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T05:24:09Z","timestamp":1768713849256,"version":"3.49.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"suppl_5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,11,15]]},"DOI":"10.1093\/cid\/civ518","type":"journal-article","created":{"date-parts":[[2015,11,10]],"date-time":"2015-11-10T00:33:10Z","timestamp":1447115590000},"page":"S521-S530","source":"Crossref","is-referenced-by-count":17,"title":["Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2\u201329 Years"],"prefix":"10.1093","volume":"61","author":[{"given":"Aldiouma","family":"Diallo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samba O.","family":"Sow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olubukola T.","family":"Idoko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddhivinayak","family":"Hirve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Findlow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Pierre","family":"Preziosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl","family":"Elie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasad S.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varsha","family":"Parulekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bou","family":"Diarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadima","family":"Cheick Haidara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatoumata","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milagritos","family":"Tapia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adebayo K.","family":"Akinsola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Adegbola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Bavdekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Juvekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Chaumont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Martellet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc F.","family":"LaForce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian D.","family":"Plikaytis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Godwin C.","family":"Enwere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxiao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Carlone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simonetta","family":"Viviani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,11,9]]},"reference":[{"issue":"suppl","key":"key\n\t\t\t\t20171013234718_CIV518C1","first-page":"3","article-title":"La m\u00e9ningite c\u00e9r\u00e9brospinale en Afrique","volume":"28","year":"1963","journal-title":"Bull World Health Organ"},{"key":"key\n\t\t\t\t20171013234718_CIV518C2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1365-3156.2006.01639.x","article-title":"Editorial: 100 years of epidemic meningitis in West Africa\u2014has anything changed?","volume":"11","year":"2006","journal-title":"Trop Med Int Health"},{"issue":"suppl 2","key":"key\n\t\t\t\t20171013234718_CIV518C3","first-page":"B13","article-title":"Epidemic meningitis due to group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution","volume":"27","year":"2009","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171013234718_CIV518C4","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/S0140-6736(03)13494-0","article-title":"Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries","volume":"361","year":"2003","journal-title":"Lancet"},{"issue":"suppl 1","key":"key\n\t\t\t\t20171013234718_CIV518C5","first-page":"A97","article-title":"The Meningitis Vaccine Project","volume":"25","year":"2007","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171013234718_CIV518C6","doi-asserted-by":"crossref","first-page":"715","DOI":"10.4161\/hv.19619","article-title":"Development of a group A meningococcal conjugate vaccine, MenAfriVac","volume":"8","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"key\n\t\t\t\t20171013234718_CIV518C7","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1003812","article-title":"Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171013234718_CIV518C8","doi-asserted-by":"crossref","first-page":"A101","DOI":"10.1016\/j.vaccine.2007.04.050","article-title":"Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults","volume":"25","year":"2007","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171013234718_CIV518C9","doi-asserted-by":"crossref","first-page":"6456","DOI":"10.1016\/j.vaccine.2012.08.004","article-title":"Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2\u201310 years: a phase II\/III double-blind randomized controlled trial","volume":"30","year":"2012","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171013234718_CIV518C10","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2014serum bactericidal antibody activity","volume":"23","year":"2005","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171013234718_CIV518C11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1586\/14760584.3.1.77","article-title":"Serologic correlates of protection for evaluating the response to meningococcal vaccines","volume":"3","year":"2004","journal-title":"Expert Rev Vaccines"},{"key":"key\n\t\t\t\t20171013234718_CIV518C12","doi-asserted-by":"crossref","first-page":"B40","DOI":"10.1016\/j.vaccine.2011.12.073","article-title":"Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience","volume":"30","year":"2012","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171013234718_CIV518C13","article-title":"A world without meningitis","author":"Meningitis Vaccine Project"},{"key":"key\n\t\t\t\t20171013234718_CIV518C14","article-title":"Meningitis","author":"World Health Organization"},{"key":"key\n\t\t\t\t20171013234718_CIV518C15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1186\/s12879-014-0663-4","article-title":"Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac","volume":"14","year":"2014","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20171013234718_CIV518C16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(13)61612-8","article-title":"Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171013234718_CIV518C17","doi-asserted-by":"crossref","first-page":"6859","DOI":"10.1016\/j.vaccine.2012.09.008","article-title":"Conducting vaccine clinical trials in sub-Saharan Africa: operational challenges and lessons learned from the Meningitis Vaccine Project","volume":"30","year":"2012","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171013234718_CIV518C18","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1128\/JCM.30.1.154-159.1992","article-title":"Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay","volume":"30","year":"1992","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20171013234718_CIV518C19","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CDLI.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis A and C serum bactericidal assays. The Multilaboratory Study Group","volume":"4","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"key\n\t\t\t\t20171013234718_CIV518C20","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJM197709292971302","article-title":"Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age","volume":"297","year":"1977","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171013234718_CIV518C21","first-page":"883","article-title":"Effect of group-A meningococcal vaccine in army recruits in Finland","volume":"2","year":"1975","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171013234718_CIV518C22","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1128\/IAI.6.5.651-656.1972","article-title":"Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and 3","volume":"6","year":"1972","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20171013234718_CIV518C23","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1128\/IAI.13.6.1654-1662.1976","article-title":"Bacillus pumilus polysaccharide cross-reactive with meningococcal group A polysaccharide","volume":"13","year":"1976","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20171013234718_CIV518C24","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1084\/jem.162.6.1837","article-title":"Escherichia coli K51 and K93 capsular polysaccharides are crossreactive with the group A capsular polysaccharide of Neisseria meningitidis. Immunochemical, biological, and epidemiological studies","volume":"162","year":"1985","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t20171013234718_CIV518C25","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.vaccine.2012.12.035","article-title":"Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt","volume":"31","author":"Dakar Discussion Group on Priorities for Research on Epidemic Meningococcal Disease in Africa;","year":"2013","journal-title":"Vaccine"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/61\/suppl_5\/S521\/20914145\/civ518.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T04:40:45Z","timestamp":1599799245000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/61\/suppl_5\/S521\/418094\/Antibody-Persistence-at-1-and-4-Years-Following-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,9]]},"references-count":25,"journal-issue":{"issue":"suppl_5","published-online":{"date-parts":[[2015,11,9]]},"published-print":{"date-parts":[[2015,11,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/civ518","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,11,15]]},"published":{"date-parts":[[2015,11,9]]}}}